Author

D. A. Scheinberg

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4 Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Research Focus:cell type annotation· 4 Organism:human· 4 Assay:proteomics· 4 Research Focus:host-pathogen & immune response· 3 Research Focus:cell signaling & trafficking· 1 Research Focus:cell-cell communication· 1 Assay:CITE-seq· 1

Frequent Co-Authors

M. G. Klatt· 4 shared T. Dao· 4 shared A. Charles· 2 shared C. A. Klebanoff· 2 shared C. Bourne· 2 shared R. S. Gejman· 2 shared S. S. Chandran· 2 shared S. S. Mun· 2 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

M. G. Klatt

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles

Z. Molvi, M. G. Klatt, T. Dao, J. Urraca, D. A. Scheinberg, R. J. O'Reilly

This study identifies tumor-specific phosphopeptides presented by multiple HLA alleles, showing allele-specific immunogenicity differences for cancer immunotherapy.

Journal for ImmunoTherapy of Cancer · Sep 28, 2023Peer-reviewedImmunology

Host-cell Interactions of Engineered T cell Micropharmacies

C. Bourne, P. Wallisch, M. Dacek, T. Gardner, S. Pierre, K. Vogt, B. Corless, M. Bah, J. Romero-Pichardo, A. Charles, K. Kurtz, D. Tan, D. A. Scheinberg

This study demonstrates that SEAKER cells, engineered T cells with prodrug-activating functions, effectively target solid tumors in immunocompetent hosts despite immune responses.

bioRxiv · Apr 5, 2023 · PreprintImmunology

Unmasking the cryptic immunopeptidome of EZH2 mutated diffuse large B-cell lymphomas through combination drug treatment

C. M. Bourne, S. S. Mun, T. Dao, Z. E. H. Aretz, R. S. Gejman, A. Daman, K. Takata, C. Steidl, M. G. Klatt, D. A. Scheinberg

The paper identifies tumor-specific MHC ligands in EZH2-mutated DLBCLs by combining epigenetic drugs and interferon gamma, expanding the immunopeptidome for immunotherapy targets.

bioRxiv · Sep 1, 2021 · PreprintImmunology

Immunogenicity of a public neoantigen derived from mutated PIK3CA

S. S. Chandran, J. Ma, M. G. Klatt, F. Dundar, C. Bandlamudi, P. C. Razavi, H. Y. Wen, B. Weigelt, P. Zumbo, S. N. Fu, L. B. Banks, W. D. Bestman, A. Drilon, D. Betel, D. A. Scheinberg, , C. A. Klebanoff

The paper investigates the immunogenicity of a public neoantigen derived from mutated PIK3CA, showing it is recognized by T cells and presents a framework for immunotherapy.

bioRxiv · Apr 8, 2021 · PreprintImmunology

Low-Dose CDK4/6 Inhibitors Induce Presentation of Pathway Specific MHC ligands as Targets for Cancer Immunotherapy

A. Charles, C. Bourne, S. S. Mun, T. Dao, Z. Aretz, T. Korontsvit, M. Klatt, D. A. Scheinberg

This study shows low-dose CDK4/6 inhibitors increase HLA ligand presentation from cell cycle proteins, creating potential targets for immunotherapy in breast cancer.

bioRxiv · Jun 18, 2020Cancer Biology

Identification of the targets of T cell receptor therapeutic agents and cells by use of a high throughput genetic platform

R. S. Gejman, H. F. Jones, M. G. Klatt, A. Y. Chang, C. Y. Oh, S. S. Chandran, T. Korontsvit, V. Zakahleva, T. Dao, C. A. Klebanoff, D. A. Scheinberg

This study introduces a high-throughput genetic platform to identify on- and off-targets of T cell receptor therapeutic agents using MHC-I ligands.

bioRxiv · Sep 1, 2019Cancer Biology